ResMed price target raised to $215 from $195 at Mizuho

Mizuho raised the firm’s price target on ResMed to $215 from $195 and keeps a Buy rating on the shares. The analyst says ResMed is now positioned to maintain $450M-plus of U.S. share gains for “much longer than anticipated” given Philips’s intentions to exit select sleep and respiratory product lines in the U.S. The firm raised the price target to reflect a longer U.S. runway for ResMed.